Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Abstract Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necros...

Full description

Bibliographic Details
Main Authors: Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert, Elke M. G. J. de Jong
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Trials
Subjects:
Psoriasis
Dose reduction
Biologics
Non-inferiority
IL-17 inhibitors
IL-23 inhibitors
Online Access:https://doi.org/10.1186/s13063-021-05681-z

Internet

https://doi.org/10.1186/s13063-021-05681-z

Similar Items